Amyloid Precursor Protein Signaling

淀粉样蛋白前体蛋白信号转导

• 批准号: 6655057
• 负责人: MARK ALLEN BOTHWELL
• 金额: $ 36.01万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6655057
• 关键词: Amyloid; Precursor; Protein; Signaling

DESCRIPTION (provided by applicant): Studies will test the hypothesis that beta-amyloid precursor protein (APP) normally functions as a signal-transducing cell surface receptor and pathological functions of APP in Alzheimer's disease reflect perturbations of that receptor function. It is proposed that APP resembles the receptor Notch in possessing two alternative signaling pathways - one propagated from the membrane-resident receptor and another propagated by nuclear translocation of the cytoplasmic domain of the receptor following gamma-secretase cleavage within the membrane-spanning sequence of the protein. Studies will employ various cell lines including COS7 cells, a neon-neuronal cell line, and NGF-differentiated PC12 cells, a neuronal cell line. Transient and stable transfection will be employed to manipulate expression of APP and proteins with which it interacts. Green fluorescent protein (GFP) and myc epitope tags will be employed to follow intracellular trafficking of beta-amyloid precursor protein following transfection. APP-GaI4/VP1 6 and APP-GaI4 fusion proteins will be expressed in reporter cell lines that express luciferase under control of a Gal4 promoter, providing a quantitative means of assessing the nuclear translocation of the APP cytoplasmic domain, and providing an assay for APP mutations and pharmacological manipulations that promote or inhibit nuclear access of the cytoplasmic domain. Mutations will be targeted to a CDK5 phosphorylation site, to a putative nuclear localization signal, to a putative PEST motif, to a Dab1/Fe65 binding site, and to putative ubiquitinization sites, and the effects on subcellular localization and nuclear translocation will be assessed. Effects of agonistic APP monoclonal antibody, beta-amyloid peptide, LRP, and alpha-2 macroglobulin on APP signaling will be assessed.

描述（由申请人提供）：研究将检验以下假设：β-淀粉样前体蛋白（APP）通常作为信号转导细胞表面受体发挥作用，并且 APP 在阿尔茨海默病中的病理功能反映了该受体功能的扰动。据推测，APP 与受体 Notch 相似，具有两种替代信号传导途径 - 一种从膜驻留受体传播，另一种通过蛋白质跨膜序列内的 γ 分泌酶裂解后受体胞质结构域的核易位传播。研究将采用各种细胞系，包括 COS7 细胞（一种神经元细胞系）和 NGF 分化的 PC12 细胞（一种神经元细胞系）。将采用瞬时和稳定转染来操纵 APP 及其相互作用的蛋白质的表达。绿色荧光蛋白 (GFP) 和 myc 表位标签将用于跟踪转染后 β-淀粉样前体蛋白的细胞内运输。 APP-Gal4/VP1 6 和 APP-Gal4 融合蛋白将在 Gal4 启动子控制下表达荧光素酶的报告细胞系中表达，提供评估 APP 胞质结构域核转位的定量方法，并提供 APP 突变和促进或抑制胞质结构域核进入的药理学操作的测定。突变将针对 CDK5 磷酸化位点、假定的核定位信号、假定的 PEST 基序、Dab1/Fe65 结合位点和假定的泛素化位点，并将评估对亚细胞定位和核转位的影响。将评估激动性 APP 单克隆抗体、β-淀粉样肽、LRP 和 α-2 巨球蛋白对 APP 信号传导的影响。